NeoChord
Saint Louis Park
About NeoChord
NeoChord is a medical device company that has developed a proprietary device that allows mitral valve repair to be performed on a beating heart through a 2 to 3-inch incision between the ribs in patients with severe, degenerative mitral valve regurgitation. In contrast, most mitral valve repair procedures are performed through a 3 to 10-inch chest incision (sternotomy) which involves cutting through the sternum, opening the rib cage, stopping the heart and placing the patient on bypass. Founded in 2007 and is based in St. Louis Park, MN.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $85.8M
- Last round: Convertible Note (May 2021)
- Website: neochord.com
- Phone: 952-698-7800
Industries & Categories
Biotechnology, Health Care, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/neochord-43875 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.